Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 2002

View Archived Issues

Possible mechanism by which vitamin E reduces the risk of prostate cancer

CYP1B1 converts resveratrol to the antileukemic agent piceatannol

Important new drug for acute lung injury launched for the first time in Japan

Novel long-acting GLP-1 analogue characterized at ADA meeting

Selective H3 receptor antagonist from Abbott effective in animal model of diet-induced obesity

Preclinical and clinical data for DPP-IV inhibitor P-32/98 discussed at ADA meeting

Microbially produced alpha-glucosidase inhibitor with promising preclinical profile

PhotoCure subscribes for shares in Anticancer Therapeutic Inventions

Both type 1 and 2 diabetics may benefit from Exubera according to phase III data

Bioenvision initiates clofarabine clinical program

First phase II/III results for Neurodex in ALS patients with emotional lability

ZT-1 tested in first-in-man trials

Ethypharm and Viatris collaborate on Flashtab formulation of tramadol

Rifalazil heads ActivBiotics' pipeline

Scientists at K.U. Leuven present novel contrast agents

Preparation and use of beta3-adrenoceptor agonists described in Lilly patent

New STAT6 inhibitors in early development at Tularik

GABA-A ligands and their use in anxiety and convulsions

Use of the Aerodose inhaler in type 2 diabetic patients

Transdermal administration of basal insulin through micropores for type 2 diabetes

AstraZeneca claims P2T antagonists for antiplatelet therapy

BioCryst describes PNP inhibitors with potential in cancer therapy

Novel antitumor naphthyridines identified by Dainippon

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...